Incidence of cardiometabolic diseases in a Lesotho HIV cohort: Evidence for policy decision-making.
AIDS
HIV
Lesotho
antiretroviral treatment
cardiometabolic disease
incidence rate
Journal
Southern African journal of HIV medicine
ISSN: 2078-6751
Titre abrégé: South Afr J HIV Med
Pays: South Africa
ID NLM: 100965417
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
03
2021
accepted:
02
05
2021
entrez:
7
7
2021
pubmed:
8
7
2021
medline:
8
7
2021
Statut:
epublish
Résumé
Antiretroviral treatment (ART) has been associated with the development of certain cardiometabolic diseases (CMDs). The burden of CMDs amongst ART-experienced patients in sub-Saharan Africa was unknown. We quantified the burden of CMDs and identified the associated risk factors in a large treatment cohort on ART at a high-volume facility in Lesotho. In this retrospective cohort study, we extracted data from the daily dispensing electronic system and routine clinical records of 785 adults on ART between 2011 and 2015 in Maseru, Lesotho. CMD was defined as a diagnosis of hypertension, diabetes mellitus or dyslipidaemia (singly or collectively). Descriptive statistics were used to describe the disease burden; Kaplan-Meier curves and cause-specific Cox proportional hazards models were fitted to examine the impact of the ART regimen and identify the risk factors associated with the occurrence of CMD. Of the 785 participants, 473 (60%) were women. The median age of the group was 42 years, interquartile range (IQR), 36-51 years. The overall incidence of CMD was 5.6 (95% confidence interval [CI] = 4.4-7.1) per 100 person-months of follow-up. The median time to onset of CMD was 16.6 months (IQR = 7.4-23.4). ART was not associated with the occurrence of CMD (cause-specific hazard ratio [CHR] = 1.55; 95% CI = 0.14-16.85; The incidence of CMD in this relatively young patient population is low yet noteworthy. We recommend that patients living with HIV and AIDS should be routinely screened for CMD. Higher BMI is generally associated with the occurrence of CMD.
Sections du résumé
BACKGROUND
BACKGROUND
Antiretroviral treatment (ART) has been associated with the development of certain cardiometabolic diseases (CMDs). The burden of CMDs amongst ART-experienced patients in sub-Saharan Africa was unknown.
OBJECTIVE
OBJECTIVE
We quantified the burden of CMDs and identified the associated risk factors in a large treatment cohort on ART at a high-volume facility in Lesotho.
METHODS
METHODS
In this retrospective cohort study, we extracted data from the daily dispensing electronic system and routine clinical records of 785 adults on ART between 2011 and 2015 in Maseru, Lesotho. CMD was defined as a diagnosis of hypertension, diabetes mellitus or dyslipidaemia (singly or collectively). Descriptive statistics were used to describe the disease burden; Kaplan-Meier curves and cause-specific Cox proportional hazards models were fitted to examine the impact of the ART regimen and identify the risk factors associated with the occurrence of CMD.
RESULTS
RESULTS
Of the 785 participants, 473 (60%) were women. The median age of the group was 42 years, interquartile range (IQR), 36-51 years. The overall incidence of CMD was 5.6 (95% confidence interval [CI] = 4.4-7.1) per 100 person-months of follow-up. The median time to onset of CMD was 16.6 months (IQR = 7.4-23.4). ART was not associated with the occurrence of CMD (cause-specific hazard ratio [CHR] = 1.55; 95% CI = 0.14-16.85;
CONCLUSION
CONCLUSIONS
The incidence of CMD in this relatively young patient population is low yet noteworthy. We recommend that patients living with HIV and AIDS should be routinely screened for CMD. Higher BMI is generally associated with the occurrence of CMD.
Identifiants
pubmed: 34230861
doi: 10.4102/sajhivmed.v22i1.1246
pii: HIVMED-22-1246
pmc: PMC8252144
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1246Informations de copyright
© 2021. The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Références
PLoS One. 2013;8(3):e59551
pubmed: 23555704
Healthcare (Basel). 2018 Feb 14;6(1):
pubmed: 29443936
BMJ Open. 2017 Mar 29;7(3):e013953
pubmed: 28360243
S Afr Med J. 2013 Oct 11;104(1):37-9
pubmed: 24388085
BMC Med. 2013 Oct 16;11:224
pubmed: 24131484
J Am Soc Hypertens. 2017 Aug;11(8):530-540
pubmed: 28689734
BMJ Open. 2017 Jul 9;7(7):e016602
pubmed: 28694350
BMJ Open. 2019 Sep 24;9(9):e025874
pubmed: 31551371
Int J Epidemiol. 2013 Dec;42(6):1754-71
pubmed: 24415610
BMC Infect Dis. 2018 Jul 6;18(1):309
pubmed: 29980190
Trop Med Int Health. 2013 May;18(5):619-31
pubmed: 23419157
Curr Opin HIV AIDS. 2009 May;4(3):176-82
pubmed: 19532047
BMJ Open Diabetes Res Care. 2017 Nov 26;5(1):e000457
pubmed: 29225896
BMJ Open. 2017 Mar 9;7(3):e013353
pubmed: 28279997
HIV AIDS (Auckl). 2018 Oct 11;10:181-192
pubmed: 30349400
Implement Sci. 2017 Aug 25;12(1):107
pubmed: 28841894
Antivir Ther. 2009;14(3):371-80
pubmed: 19474471
Braz J Infect Dis. 2013 Jul-Aug;17(4):438-43
pubmed: 23735423
BMC Res Notes. 2014 Jun 21;7:380
pubmed: 24950924
Open AIDS J. 2015 Oct 20;9:51-9
pubmed: 26587072
J Antimicrob Chemother. 2012 Apr;67(4):1001-9
pubmed: 22232517
AIDS. 2018 Mar 27;32(6):773-782
pubmed: 29369158
PLoS One. 2016 Mar 23;11(3):e0150970
pubmed: 27008536